Journal article
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database
Abstract
Daratumumab (dara) has significantly altered the therapeutic landscape of multiple myeloma (MM), especially in the relapsed setting. This study aimed to evaluate the outcomes of dara-containing regimens in the Canadian real-world setting among relapsed and refractory MM available within the national Canadian Myeloma Research Group Database (CMRG-DB). A total of 583 MM patients who received dara-based therapy in second-line or later treatment …
Authors
LeBlanc R; Mian H; Reece D; Masih‐Khan E; Kardjadj M; Jimenez‐Zepeda VH; McCurdy A; Song K; Sebag M; Louzada M
Journal
British Journal of Haematology, Vol. 198, No. 1, pp. 93–102
Publisher
Wiley
Publication Date
July 2022
DOI
10.1111/bjh.18172
ISSN
0007-1048